Endothelin potentiates TRPV1 via ETA receptor-mediated activation of protein kinase C
© Plant et al; licensee BioMed Central Ltd. 2007
Received: 10 May 2007
Accepted: 14 November 2007
Published: 14 November 2007
Endothelin-1 (ET-1) both stimulates nociceptors and sensitizes them to noxious stimuli, an effect probably mediated by the ETA receptor (ETAR) expressed in sensory neurons. The cellular mechanisms of this ET-1-mediated effect are only poorly understood. TRPV1, the heat-, pH- and capsaicin-sensitive cation channel already known to be modulated by a number of cellular mediators released in response to noxious stimuli and during inflammation, is a potential target for the action of ET-1.
We studied the effects of ET-1 on TRPV1 in sensory neurons from the dorsal root ganglion (DRG) and in HEK293 cells coexpressing TRPV1 and the ETAR. Specific 125I-ET-1 binding sites (817 ± 92 fmol/mg) were detected in membrane preparations of DRG with an ETAR/ETBR ratio of 60:40. In an immunofluorescence analysis, coexpression of TRPV1 and the ETAR was found in a subpopulation of primary sensory neurons. ET-1 strongly potentiated capsaicin-induced TRPV1 currents in some neurons, and in HEK293 cells co-expressing TRPV1 and the ETAR. Weaker potentiation was observed in HEK293 cells coexpressing TRPV1 and the ETBR. ETAR activation also increased responses to low pH and heat. In HEK293 cells, strong potentiation of TRPV1 like that induced by ET-1 via the ETAR could be induced by PKC activation, but not with activators of the adenylyl cyclase or the PKA pathway. Furthermore, inhibition of PKC with bisindolylmaleimide X (BIM X) or mutation of the PKC phosphorylation site S800 completely prevented ETAR-mediated potentiation.
We conclude that ET-1 potentiates TRPV1 by a PKC-dependent mechanism and that this could play a major role in the algogenic and hyperalgesic effects of ET-1 described in previous studies.
Endothelin is one of many local mediators that are important in pain generation and the modulation of nociceptor responsiveness to painful stimuli. The endothelins, ET-1, ET-2 and ET-3, are vasoactive peptides, originally cloned from endothelial cells , but also produced by other cell types, including some tumor cells [2–5]. Endothelins act on ETA and ETB receptors (ETARs and ETBRs) [6, 7], both G protein-coupled receptors that can activate multiple G protein types and influence various signaling pathways .
ET-1 injection excites nociceptors [9, 10] and induces nocifensive behaviour in animals [11–13], and severe pain and tactile allodynia in humans . ET receptor antagonists have been reported to reduce neuropathic and inflammatory pain, and pain in patients with metastatic prostate cancer (see [15, 16] for reviews). Given the number of reports on the involvement of ET-1 in nociception, relatively little is known about the signaling cascade and effectors that lead to the nociceptive responses to ET-1 in primary sensory neurons.
Activation of the ETAR, which is expressed in sensory neurons , results in small increases in [Ca2+]i in a sensory neuron-derived cell line  and DRG neurons , and in a protein kinase C(PKC)-ε-mediated potentiation of Ca2+ responses to capsaicin . The increased responsiveness of sensory neurons may result from an ETAR-mediated lowering of the threshold for activation of tetrodotoxin (TTX)-insensitive Na+ channels , but may involve other effectors. One possibility is that ET-1 affects other channels like the nonselective cation channel TRPV1, an integrator of a number of noxious stimuli, including heat (> 42°C), capsaicin, endocannabinoids and H+ , which is essential for thermal hyperalgesia in inflammation [22, 23]. TRPV1 activation results in depolarization and excitation of sensory neurons. In a preliminary conference report we showed that activation of the ETAR potentiated TRPV1 responses to capsaicin in HEK 293 cells . A number of modulators sensitize nociceptors by potentiating TRPV1 responses [25–30]. Possible mechanisms involved in potentiation are phosphorylation via PKC-ε  and protein kinase A (PKA) [32, 33], disinhibition of TRPV1 by hydrolysis of phosphatidylinositol bisphosphate (PIP2) , or modulation via phophatidylinositol-3-kinase and extracellular signal-related kinases 1/2 .
In this study, we investigated ET receptor expression in DRG and, using the patch clamp technique, the effects of ET-1 on responses to capsaicin in DRG neurons. A subpopulation of neurons responded to ET-1 with a potentiation of the capsaicin-mediated responses. To investigate the signaling pathways involved in potentiation, we studied the effects of ET-1 in HEK293 cells coexpressing the ETAR and TRPV1.
Endothelin receptors in dorsal root ganglion neurons
The expression of endothelin receptor subtypes in the rat lumbar DRG was analyzed in binding experiments using 125I-ET-1 as the radioligand. Saturation binding analysis of membranes derived from isolated lumbar DRG (L4 – L5) revealed a maximal binding capacity of 817 ± 92 fmol/mg (mean ± SD of three measurements performed in duplicate). When the ETAR-selective antagonist BQ123 or the ETBR-selective agonist IRL1620 were used as competing ligands (to determine the amount of ETAR or ETBR expression), binding capacities of 503 ± 115 and 313 ± 113 fmol/mg protein were obtained, respectively. Thus, both ETARs and ETBRs are expressed in the rat DRG with an expression ratio of 60:40.
Effects of ET-1 in isolated sensory neurons
Effects of ET-1 on HEK293 cells transiently transfected with TRPV1 and the ETA or ETB receptor
In ETAR-expressing cells, application of ET-1 also potentiated currents activated by low pH or by heat (Fig. 3D – J). H+-activated TRPV1 currents were evoked by application of a solution of pH 5.1, a pH which produces a submaximal TRPV1 activation, preceded by the application of a solution of pH 6.8 to desensitize endogenous acid-sensing ion channels (ASICs; Fig. 3D) . Application of ET-1 resulted in a 9.9 ± 1.3-fold (n = 12) potentiation of the first response to pH 5.1 after ET-1 application (Fig. 3D – F), and a significant potentiation of subsequent responses (Fig. 3D, F). Current responses of TRPV1 to heat were recorded upon raising the temperature from room temperature to 44°C (Fig. 3G). In controls, consecutive responses had similar amplitudes (Fig. 3G, left). ET-1 augmented the responses to the increase in temperature (2.5 ± 0.6-fold, n = 10, for the first response after ET-1, Fig. 3I) and, as illustrated for the experiment in Fig.3G, 3H, shifted the threshold for TRPV1 activation to lower temperatures (Fig. 3J).
Role of protein kinases in the ETA receptor-mediated potentiation of TRPV1
Synopsis of ET-1-mediated cAMP and inositol phosphate formation via ETA and ETB receptors
-fold of control
-fold of control
formation of inositol phosphates
22.3 ± 2.5
4.5 ± 1.2
18 ± 2.0
7.3 ± 1.7
formation of cAMP
34 ± 10.6
13.3 ± 3.2
We show here that DRG neurons mainly express ETARs and that their expression partially overlaps with the expression of TRPV1. We also show that ET-1 potently modulates the functional activity of TRPV1 in a subpopulation of sensory neurons and in HEK293 cells co-expressing the ETAR and TRPV1. A significant modulation of TRPV1 activity was also found for HEK293 cells co-expressing TRPV1 and ETBRs.
Even though the ETAR can stimulate pathways leading to both PKA and PKC activation, receptor-mediated potentiation of TRPV1 in HEK293 cells was predominantly mediated by PKC. Evidence for this is that ET-1 effects were completely inhibited by the PKC inhibitor BIM X, and prevented in the PKC phosphorylation site mutant TRPV1-S800A. There is also a strong similarity between the extent of potentiation by ET-1 and that elicited by the PKC-activating phorbol ester PMA. In contrast to the effects of PKC activation and inhibition, the effects of PKA activation by forskolin were comparatively weak, and dbcAMP had no significant effect. Potentiation by ET-1 also persisted in the presence of H-89, an inhibitor of PKA. In addition, some potentiation was observed with the ETBR which did not increase cAMP. These results indicate that, under the conditions used, i.e. in the absence of extracellular Ca2+, ET-1-mediated potentiation is unlikely to occur via Gs and AC, nor to a great extent via PKC-mediated activation of AC. Because the cAMP/PKA pathway acts, at least partly, by decreasing Ca2+-dependent desensitization [32, 43], we cannot rule out that this pathway provides an additional component of potentiation of TRPV1 by ET-1 at physiological Ca2+ concentrations. Our work lends support to a recent study showing that PKC-ε is involved in the ET-1-mediated enhancement of capsaicin-induced Ca2+ increases in sensory neurons, but which did not show that TRPV1 is the target for PKC-ε-mediated phosphorylation . Our observation is also in line with the finding that S800 is crucially involved in PMA-mediated sensitization of TRPV1 via PKC-ε . From our data, we cannot rule out that different pathways may be involved in the responses to ET-1 in sensory neurons, but there is a striking similarity between the effects in DRGs and in HEK293 cells. The evidence for an involvement of PKC in potentiation by ET-1 supports studies showing an involvement of PKC in potentiation of TRPV1 by bradykinin via B2 receptors [26, 27, 31], ATP via Gq-coupled P2Y1 receptors [41, 45], the chemokine CCL3 via CCR1 , 5-HT via 5-HT2 receptors , and in some of the effects of prostaglandins via EP1 or IP receptors , but contrasts with that showing that the effects of bradykinin and NGF result from PLC-mediated release of TRPV1 from inhibition by PIP2 [28, 49]. The increase of TRPV1 currents in response to PKC activation in sensory neurons most likely results from a phosphorylation-induced increase in the activity of channels at a given agonist concentration , but has also been attributed to an increased recruitment of intracellularly-stored vesicles carrying TRPV1 to the plasma membrane .
In DRG neurons, we observed two effects of ET-1; potentiation of responses to capsaicin and, in a smaller population of neurons, the activation of an inward current. These effects are very similar to those of bradykinin, which also activates an inward current, most likely a cation current, in some sensory neurons [26, 52, 53], and potentiates currents through TRPV1 [26, 27, 31]. It remains unclear whether the channel activated by bradykinin is TRPV1 because not all heat-sensitive neurons with temperature thresholds of 42°C, characteristic for TRPV1, show a current response to bradykinin . On the other hand, high concentrations of bradykinin can shift the temperature threshold of TRPV1 sufficiently to produce a current at room temperature . The inward current activated by ET-1 was not characterized directly, but it differed from TRPV1 currents in the absence of current noise for currents of comparable amplitudes, and there was no link between the amplitude of the ET-1-activated and capsaicin-activated currents. Other possible candidates for the ET-1-activated channel include other cation channels, like e.g. TRPA1, which has been shown to be activated by bradykinin . It is also notable that in HEK293 cells co-transfected with TRPV1 and ETARs or ETBRs, ET-1 did not induce a rapidly activating and inactivating inward current like that in DRG neurons, but did result in a small slow increase in an outwardly-rectifying current that resembled TRPV1. Thus, the molecular basis and nature of the fast inward current seen in DRG neurons in response to ET-1 remains to be clarified.
Our data at the cellular level support a role of potentiation of currents through TRPV1 in ET-1-induced excitation of nociceptors by increasing their sensitivity to algogenic stimuli. Furthermore, ET-1 could produce an initial transient excitation of some neurons by the activation of an inward current. Previous studies have postulated that part of the effects of ET-1 on nociception occur via modulation of TTX-resistant Na+ channels  shifting their potential dependence of activation to more negative membrane potentials leading to enhanced excitability of the sensory neurons. Effects on Na+ channels have been observed with the hyperalgesic modulators PGE2, 5-HT, epinephrine and adenosine (for reviews see [55, 56]), and may be mediated by PKA or PKC activation . Thus, the actions of ET-1 in sensory neurons involve contributions of Na+ channels and TRPV1, and may be mediated by both PKA and PKC. By its concerted actions on TRPV1 and Na+ channels, ET-1 could increase the depolarization of sensory endings in response to noxious stimuli and concomitantly reduce the threshold for activation of a population of Na+ channels.
The effects of ET-1 on nociception are complex. Different experimental models have been used to study the role of ET-1 in nociception, and receptor subtype-specific agonists and antagonists to identify the ET receptor subtype mediating the effects. The pronociceptive actions of ET-1 have been reported to involve either ETARs [9, 10, 58–62] or ETBRs [63, 64], or both ETARs and ETBRs [12, 65, 66]. Our results indicate that the ETAR is expressed in sensory neurons and could contribute to the algogenic effects of ET-1 by sensitizing TRPV1. This suggestion is supported by a recent study on mouse DRGs which showed that the Ca2+ release in response to ET-1, and the potentiatory effect of ET-1 on capsaicin-induced Ca2+ responses are mediated exclusively by ETARs . Even though the ETBR is able to potentiate TRPV1 in HEK293 cells, the low level of ETBR expression in DRG neurons indicates that the algogenic effects of ETBR agonists [12, 64] and the analgesic effects of ETBR antagonists [63–66] are more likely to result from indirect effects on the ETBR in Schwann and other glial cells where receptor expression is high . It is difficult to extrapolate from data obtained on single isolated neurons to the situation in vivo, but our results could explain the excitatory effects of ET-1 injection on nociceptors and some of the amplification of responses to thermal and mechanical stimuli. The rapid inward current, if occurring in the periphery, could rapidly excite some ET receptor-expressing nociceptive neurons. Thereafter, the potentiation of TRPV1 could be responsible for the excitation, and for the hyperalgesia and allodynia seen after ET-1 application. Potentiation of TRPV1 with high ET-1 concentrations occurs rapidly and, although it decreases with time, by extrapolating our data (e.g. those in Fig. 2A) can probably persist for several tens of minutes. It is more difficult to explain the TRPV1-mediated prolongation of tactile allodynia in response to low ET-1 concentrations where a role of TRPV1 is only significant at times longer than 30 minutes after ET-1 application . While the role of the ETAR in the action of ET-1 on nociception is relatively clear, the role of the ETBR is less well understood. The ETBR in glial cells and possibly in neurons is likely to have pronociceptive effects, whereas the ETBR in keratinocytes has been reported to mediate the analgesic effects of ET-1 and ETB agonists by inducing the release of β-endorphin .
Our results show that ET-1 potentiates TRPV1 via a PKC-mediated effect and we suggest that this could be responsible for a major part of the pain-producing and hyperalgesic effects of ET-1 observed in previous studies.
Isolation and culture of DRG neurons
Dorsal root ganglia (DRG) were isolated as described recently . In brief, DRG from lumbar segments L4 – L5 of male Wistar rats were isolated and placed in Minimal Essential Medium (MEM, Biochrom AG, Berlin, Germany) at 4°C. Thereafter, they were sequentially digested with collagenase (type II; 3 mg/ml) for 50 min at 37°C, and trypsin (type I; 0.25 mg/ml) for 10 min at 37°C. After careful mechanical dissociation, cells were washed twice and resuspended in fresh medium supplemented with 10% horse serum, 50 ng/ml NGF, 50 U/ml penicillin and 50 μg/ml streptomycin. Neurons were seeded on poly-l-lysine-coated glass coverslips in 6-well culture plates 4 – 36 h before the experiments. Neurons were kept at 37°C in an atmosphere of 5% CO2.
Generation of plasmids encoding mutant TRPV1
To investigate the role of PKC-mediated phosphorylation of TRPV1, a plasmid was generated, which encodes a mutant TRPV1 in which serine 800 is replaced by alanine (TRPV1-S800A). Site-directed mutagenesis was performed with the QuickChange mutagenesis kit (Stratagene, La Jolla, CA), using a plasmid encoding a rat TRPV1-YFP fusion protein  and appropriate sense and antisense oligonucleotides spanning the mutated triplet and 15 flanking nucleotides. The construct was verified by DNA sequencing.
HEK293 cells were cultured in MEM-Earle medium (Biochrom), supplemented with 10% (v/v) fetal calf serum (Gibco/Invitrogen, Karlsruhe, Germany) and 100 U/ml penicillin and 100 μg/ml streptomycin. Cells were plated onto glass cover slips 24 – 48 h prior to transfection. The cells were transiently transfected with 1 μg of the plasmid pTRPV1-YFP  and 2 μg of the plasmid pETA-myc DNA  or the plasmid containing the FLAG-tagged ETB DNA  using 6 μl of FuGENE 6 Transfection Reagent (Roche Diagnostics, Mannheim, Germany) in 94 μl of OptiMEM medium (Gibco/Invitrogen) per 85 mm dish. In some experiments, cells were transfected 1 – 2 days after plating into 35 mm dishes using 9 μl TransIT (Mirus, Madison, WI) in serum-free MEM-Earle medium, subsequently trypsinized and plated onto glass coverslips 2 days after transfection. No differences were observed between results obtained with the two methods. Electrophysiological experiments were performed 24 – 72 h after transfection.
Immunofluorescence analysis was performed as described recently . Freshly isolated DRG were embedded in Tissue-Tek compound (OCT, Miles Inc., Elkhart, USA) and frozen. Consecutive sections (9 μm) were prepared with a cryostat and mounted onto gelatin-coated slides. To prevent non-specific binding, the sections were incubated for 60 min in PBS containing 0.3% Triton X-100, 1% BSA, 4% goat serum, and 4% horse serum (block solution). The sections were then incubated overnight at 4°C with a guinea pig polyclonal antibody against TRPV1 (1:1,000; Chemicon, CA, USA) or S100 Antigen (1:200; Abcam, Cambridge, UK) in combination with a peptide-derived rabbit polyclonal antibody directed against the C terminus of the ETAR (1:100) (Plant et al., 2006) or against the N terminus of the ETBR (1:100) . The tissue sections were washed with PBS and then incubated with Texas red-conjugated goat anti-rabbit antibody and FITC-conjugated donkey anti-guinea pig antibody. Thereafter, sections were washed with PBS, mounted in vectashield (Vector Laboratories, Burlingame, CA, USA) and viewed with a Zeiss 510 laser scanning microscope (Zeiss, Oberkochen, Germany).
cAMP and inositol phosphate measurements
Determination of inositol phosphates and of cAMP was performed as described previously . In brief, HEK293 cells stably expressing ETARs or ETBRs were seeded onto 24-well plates (100,000 cells/well). For inositol phosphate determination, cells were incubated the following day with 74 kBq/ml myo- [2-3H]inositol (specific activity 370 – 740 GBq/mmol; Amersham Biosciences) for 20 h at 37°C. Cells were then washed with DMEM, 10 mM HEPES, 0.5% BSA, 10 mM LiCl, and finally stimulated with buffer or increasing concentrations of ET-1 (10 pM to 100 nM) for 60 min at 37°C. Cells were then lysed with 0.1 M NaOH, and inositol phosphates isolated from cleared supernatants by anion exchange chromatography.
For the determination of cAMP, cells were washed with 1 ml of stimulation medium (DMEM without fetal calf serum, supplemented with 10 mM HEPES, 0.5% BSA, 0.25 mM 3-isobutyl-1-methylxanthine) and incubated for 30 min at 37°C with buffer or increasing concentrations of ET-1 (10 pM to 100 nM). Cells were extracted with 750 μl of 0.1% trifluoroacetic acid, 0.005% Triton X-100 for 30 min at 4°C. After acetylation of the samples, the cAMP content was determined using 125I-cAMP-tyrosylmethylester (10,000 cpm, specific activity 81.4 TBq/mM, Biotrend, FRG) and polyclonal rabbit anti-cAMP-antibody (final dilution 1:160,000). After an overnight incubation at 4°C, the antibody-bound fraction was precipitated, and the radioactivity of the precipitate was determined in a β-counter.
125I-ET-1 binding analysis
Binding analysis was performed as described [73, 74]. In brief, membranes (5 μg) of DRGs were incubated in a final volume of 200 μl Tris/BAME buffer with increasing concentrations of 125I-ET-1 (18 to 1000 pM) in the absence or presence of unlabelled ET-1 (1 μM) (to detect ETARs and ETBRs) for 2 hours at 25°C. The ratio of ETA and ETBR expression was determined by 125I-ET-1 saturation binding analysis using ET-1 (1 μM, total binding), IRL1620 (1 μM, ETBR-specific binding) or BQ123 (10 μM, ETAR-specific binding) as competing ligands. The samples were then transferred onto GF/C filters (Whatman International Ltd., Maidstone, UK), and washed twice with PBS using a Brandel cell harvester. Radioactivity was determined in a γ-counter. Data were analyzed with RadLig Software 4.0 (Cambridge, UK).
Patch clamp recordings
Recordings of whole cell currents from single cells were made with an EPC-7 or EPC-10 amplifier using Pulse software (HEKA, Lambrecht, Germany) as described previously . Experiments were performed using the standard whole cell mode of the patch clamp technique. Cells were held at a potential of -60 mV and the current recorded using XChart (HEKA). In HEK293 cells, ramps from -100 to +100 mV with a duration of 400 ms were applied at a frequency of 0.2 Hz. Ramp data were acquired at a frequency of 4 kHz after filtering at 1 kHz.
The standard pipette solution contained 100 mM CH3O3SCs (cesium methane sulfonate), 25 mM CsCl, 3 mM MgCl2, 2 mM Na2ATP, 3.62 mM CaCl2, 10 mM EGTA, 30 mM HEPES (pH 7.2 with CsOH). Pipette tips were filled with the same solution without ATP to avoid the activation of purinergic receptors prior to seal formation. The standard extracellular solution contained: 140 mM NaCl, 5 mM CsCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES (pH 7.4 with NaOH). For Ca2+-free solutions, Ca2+ was omitted and 0.5 mM EGTA added. Experiments were performed at room temperature 20 – 25°C. Solutions were applied by bath perfusion. In most cases, with the exception of Fig. 2B, which was not used for quantification of the response, capsaicin was applied until currents approached a steady state value. In experiments on the effects of heat, bath temperature was measured using a thermistor placed close to the cell studied and recorded using XChart. The test solution was preheated to appropriate temperatures using a water jacket connected to a water bath.
This work was supported by grants from the DFG and Fonds der Chemischen Industrie. We thank Inge Reinsch and Nadine Albrecht for technical assistance.
- Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332: 411–415. 10.1038/332411a0PubMedView ArticleGoogle Scholar
- Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD, Coligan JE, Kehrl JH, Fauci AS: Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990, 172: 1741–1748. 10.1084/jem.172.6.1741PubMedView ArticleGoogle Scholar
- Giaid A, Gibson SJ, Ibrahim BN, Legon S, Bloom SR, Yanagisawa M, Masaki T, Varndell IM, Polak JM: Endothelin 1, an endothelium-derived peptide, is expressed in neurons of the human spinal cord and dorsal root ganglia. Proc Natl Acad Sci U S A 1989, 86: 7634–7638. 10.1073/pnas.86.19.7634PubMed CentralPubMedView ArticleGoogle Scholar
- MacCumber MW, Ross CA, Snyder SH: Endothelin in brain: receptors, mitogenesis, and biosynthesis in glial cells. Proc Natl Acad Sci U S A 1990, 87: 2359–2363. 10.1073/pnas.87.6.2359PubMed CentralPubMedView ArticleGoogle Scholar
- Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, Simons JW: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995, 1: 944–949. 10.1038/nm0995-944PubMedView ArticleGoogle Scholar
- Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, Masaki T: Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990, 348: 732–735. 10.1038/348732a0PubMedView ArticleGoogle Scholar
- Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990, 348: 730–732. 10.1038/348730a0PubMedView ArticleGoogle Scholar
- Alexander SP, Mathie A, Peters JA: Endothelin. Br J Pharmacol 2006, 147 Suppl 3: S33–34. 10.1038/sj.bjp.0706612View ArticleGoogle Scholar
- Davar G, Hans G, Fareed MU, Sinnott C, Strichartz G: Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve. Neuroreport 1998, 9: 2279–2283. 10.1097/00001756-199807130-00025PubMedView ArticleGoogle Scholar
- Gokin AP, Fareed MU, Pan HL, Hans G, Strichartz GR, Davar G: Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats. J Neurosci 2001, 21: 5358–5366.PubMedGoogle Scholar
- Raffa RB, Schupsky JJ, Lee DK, Jacoby HI: Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model. J Pharmacol Exp Ther 1996, 278: 1–7.PubMedGoogle Scholar
- Raffa RB, Schupsky JJ, Jacoby HI: Endothelin-induced nociception in mice: mediation by ETA and ETB receptors. J Pharmacol Exp Ther 1996, 276: 647–651.PubMedGoogle Scholar
- Ferreira SH, Romitelli M, de Nucci G: Endothelin-1 participation in overt and inflammatory pain. J Cardiovasc Pharmacol 1989, 13 Suppl 5: S220–2.PubMedView ArticleGoogle Scholar
- Dahlof B, Gustafsson D, Hedner T, Jern S, Hansson L: Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction. J Hypertens 1990, 8: 811–817. 10.1097/00004872-199009000-00004PubMedView ArticleGoogle Scholar
- Davar G: Endothelin-1 and metastatic cancer pain. Pain Med 2001, 2: 24–27. 10.1046/j.1526-4637.2001.002001024.xPubMedView ArticleGoogle Scholar
- Nicol GD: ET--phone the pain clinic. Trends Neurosci 2004, 27: 177–80; discussion 180. 10.1016/j.tins.2004.02.001PubMedView ArticleGoogle Scholar
- Pomonis JD, Rogers SD, Peters CM, Ghilardi JR, Mantyh PW: Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception. J Neurosci 2001, 21: 999–1006.PubMedGoogle Scholar
- Zhou QL, Strichartz G, Davar G: Endothelin-1 activates ET(A) receptors to increase intracellular calcium in model sensory neurons. Neuroreport 2001, 12: 3853–3857. 10.1097/00001756-200112040-00050PubMedView ArticleGoogle Scholar
- Yamamoto H, Kawamata T, Ninomiya T, Omote K, Namiki A: Endothelin-1 enhances capsaicin-evoked intracellular Ca2+ response via activation of endothelin a receptor in a protein kinase Cepsilon-dependent manner in dorsal root ganglion neurons. Neuroscience 2006, 137: 949–960. 10.1016/j.neuroscience.2005.09.036PubMedView ArticleGoogle Scholar
- Zhou Z, Davar G, Strichartz G: Endothelin-1 (ET-1) selectively enhances the activation gating of slowly inactivating tetrodotoxin-resistant sodium currents in rat sensory neurons: a mechanism for the pain-inducing actions of ET-1. J Neurosci 2002, 22: 6325–6330.PubMedGoogle Scholar
- Julius D, Basbaum AI: Molecular mechanisms of nociception. Nature 2001, 413: 203–210. 10.1038/35093019PubMedView ArticleGoogle Scholar
- Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D: Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000, 288: 306–313. 10.1126/science.288.5464.306PubMedView ArticleGoogle Scholar
- Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA: Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000, 405: 183–187. 10.1038/35012076PubMedView ArticleGoogle Scholar
- Plant TD, Zollner C, Mousa SA, Oksche A: Endothelin-1 potentiates capsaicin-induced TRPV1 currents via the endothelin A receptor. Exp Biol Med (Maywood) 2006, 231: 1161–1164.Google Scholar
- Lopshire JC, Nicol GD: The cAMP transduction cascade mediates the prostaglandin E2 enhancement of the capsaicin-elicited current in rat sensory neurons: whole-cell and single-channel studies. J Neurosci 1998, 18: 6081–6092.PubMedGoogle Scholar
- Cesare P, McNaughton P: A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc Natl Acad Sci U S A 1996, 93: 15435–15439. 10.1073/pnas.93.26.15435PubMed CentralPubMedView ArticleGoogle Scholar
- Sugiura T, Tominaga M, Katsuya H, Mizumura K: Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 2002, 88: 544–548.PubMedGoogle Scholar
- Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, Julius D: Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 2001, 411: 957–962. 10.1038/35082088PubMedView ArticleGoogle Scholar
- Premkumar LS, Ahern GP: Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000, 408: 985–990. 10.1038/35050121PubMedView ArticleGoogle Scholar
- Tominaga M, Wada M, Masu M: Potentiation of capsaicin receptor activity by metabotropic ATP receptors as a possible mechanism for ATP-evoked pain and hyperalgesia. Proc Natl Acad Sci U S A 2001, 98: 6951–6956. 10.1073/pnas.111025298PubMed CentralPubMedView ArticleGoogle Scholar
- Cesare P, Dekker LV, Sardini A, Parker PJ, McNaughton PA: Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999, 23: 617–624. 10.1016/S0896-6273(00)80813-2PubMedView ArticleGoogle Scholar
- Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW: cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002, 35: 721–731. 10.1016/S0896-6273(02)00802-4PubMedView ArticleGoogle Scholar
- Rathee PK, Distler C, Obreja O, Neuhuber W, Wang GK, Wang SY, Nau C, Kress M: PKA/AKAP/VR-1 module: A common link of Gs-mediated signaling to thermal hyperalgesia. J Neurosci 2002, 22: 4740–4745.PubMedGoogle Scholar
- Zhuang ZY, Xu H, Clapham DE, Ji RR: Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 2004, 24: 8300–8309. 10.1523/JNEUROSCI.2893-04.2004PubMedView ArticleGoogle Scholar
- Berti-Mattera LN, Gariepy CE, Burke RM, Hall AK: Reduced expression of endothelin B receptors and mechanical hyperalgesia in experimental chronic diabetes. Exp Neurol 2006, 201: 399–406. 10.1016/j.expneurol.2006.04.034PubMedView ArticleGoogle Scholar
- Gunthorpe MJ, Smith GD, Davis JB, Randall AD: Characterisation of a human acid-sensing ion channel (hASIC1a) endogenously expressed in HEK293 cells. Pflügers Archiv European Journal of Physiology 2001, 442: 668–674. 10.1007/s004240100584PubMedView ArticleGoogle Scholar
- Aramori I, Nakanishi S: Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells. J Biol Chem 1992, 267: 12468–12474.PubMedGoogle Scholar
- Oda K, Fujitani Y, Watakabe T, Inui T, Okada T, Urade Y, Okuda-Ashitaka E, Ito S: Endothelin stimulates both cAMP formation and phosphatidylinositol hydrolysis in cultured embryonic bovine tracheal cells. FEBS Lett 1992, 299: 187–191. 10.1016/0014-5793(92)80244-BPubMedView ArticleGoogle Scholar
- Eguchi S, Hirata Y, Marumo F: Endothelin subtype B receptors are coupled to adenylate cyclase via inhibitory G protein in cultured bovine endothelial cells. J Cardiovasc Pharmacol 1993, 22 Suppl 8: S161–3.PubMedView ArticleGoogle Scholar
- Gohla A, Offermanns S, Wilkie TM, Schultz G: Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation. J Biol Chem 1999, 274: 17901–17907. 10.1074/jbc.274.25.17901PubMedView ArticleGoogle Scholar
- Numazaki M, Tominaga T, Toyooka H, Tominaga M: Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 2002, 277: 13375–13378. 10.1074/jbc.C200104200PubMedView ArticleGoogle Scholar
- Bhave G, Hu HJ, Glauner KS, Zhu W, Wang H, Brasier DJ, Oxford GS, Gereau RW: Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S A 2003, 100: 12480–12485. 10.1073/pnas.2032100100PubMed CentralPubMedView ArticleGoogle Scholar
- Mohapatra DP, Nau C: Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 2003, 278: 50080–50090. 10.1074/jbc.M306619200PubMedView ArticleGoogle Scholar
- Mandadi S, Tominaga T, Numazaki M, Murayama N, Saito N, Armati PJ, Roufogalis BD, Tominaga M: Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-mediated phosphorylation at S800. Pain 2006, 123: 106–116. 10.1016/j.pain.2006.02.016PubMedView ArticleGoogle Scholar
- Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C, Suzuki N, Inoue K, Gachet C, Noguchi K, Tominaga M: Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 2003, 23: 6058–6062.PubMedGoogle Scholar
- Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, Oppenheim JJ: A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A 2005, 102: 4536–4541. 10.1073/pnas.0406030102PubMed CentralPubMedView ArticleGoogle Scholar
- Sugiura T, Bielefeldt K, Gebhart GF: TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. J Neurosci 2004, 24: 9521–9530. 10.1523/JNEUROSCI.2639-04.2004View ArticleGoogle Scholar
- Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, Tominaga M: Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 2005, 1: 3. 10.1186/1744-8069-1-3PubMed CentralPubMedView ArticleGoogle Scholar
- Prescott ED, Julius D: A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 2003, 300: 1284–1288. 10.1126/science.1083646PubMedView ArticleGoogle Scholar
- Vellani V, Mapplebeck S, Moriondo A, Davis JB, McNaughton PA: Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 2001, 534: 813–825. 10.1111/j.1469-7793.2001.00813.xPubMed CentralPubMedView ArticleGoogle Scholar
- Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A: Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004, 279: 25665–25672. 10.1074/jbc.M311515200PubMedView ArticleGoogle Scholar
- Burgess GM, Mullaney I, McNeill M, Dunn PM, Rang HP: Second messengers involved in the mechanism of action of bradykinin in sensory neurons in culture. J Neurosci 1989, 9: 3314–3325.PubMedGoogle Scholar
- Nicol GD, Cui M: Enhancement by prostaglandin E2 of bradykinin activation of embryonic rat sensory neurones. J Physiol 1994, 480: 485–492.PubMed CentralPubMedView ArticleGoogle Scholar
- Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, Patapoutian A: Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 2004, 41: 849–857. 10.1016/S0896-6273(04)00150-3PubMedView ArticleGoogle Scholar
- McCleskey EW, Gold MS: Ion channels of nociception. Annu Rev Physiol 1999, 61: 835–856. 10.1146/annurev.physiol.61.1.835PubMedView ArticleGoogle Scholar
- Lai J, Porreca F, Hunter JC, Gold MS: Voltage-gated sodium channels and hyperalgesia. Annu Rev Pharmacol Toxicol 2004, 44: 371–397. 10.1146/annurev.pharmtox.44.101802.121627PubMedView ArticleGoogle Scholar
- Gold MS, Levine JD, Correa AM: Modulation of TTX-R INa by PKC and PKA and their role in PGE2-induced sensitization of rat sensory neurons in vitro. J Neurosci 1998, 18: 10345–10355.PubMedGoogle Scholar
- Piovezan AP, D'Orleans-Juste P, Souza GE, Rae GA: Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation. Br J Pharmacol 2000, 129: 961–968. 10.1038/sj.bjp.0703154PubMed CentralPubMedView ArticleGoogle Scholar
- Fareed MU, Hans GH, Atanda A, Strichartz GR, Davar G: Pharmacological characterization of acute pain behavior produced by application of endothelin-1 to rat sciatic nerve. Journal of Pain 2000, 1: 46–53. 10.1016/S1526-5900(00)90087-7View ArticleGoogle Scholar
- Jarvis MF, Wessale JL, Zhu CZ, Lynch JJ, Dayton BD, Calzadilla SV, Padley RJ, Opgenorth TJ, Kowaluk EA: ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain. Eur J Pharmacol 2000, 388: 29–35. 10.1016/S0014-2999(99)00865-1PubMedView ArticleGoogle Scholar
- Wacnik PW, Eikmeier LJ, Ruggles TR, Ramnaraine ML, Walcheck BK, Beitz AJ, Wilcox GL: Functional interactions between tumor and peripheral nerve: morphology, algogen identification, and behavioral characterization of a new murine model of cancer pain. J Neurosci 2001, 21: 9355–9366.PubMedGoogle Scholar
- Peters CM, Lindsay TH, Pomonis JD, Luger NM, Ghilardi JR, Sevcik MA, Mantyh PW: Endothelin and the tumorigenic component of bone cancer pain. Neuroscience 2004, 126: 1043–1052. 10.1016/j.neuroscience.2004.04.027PubMedView ArticleGoogle Scholar
- Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH: Endothelin B receptor modulates inflammatory pain and cutaneous inflammation. Mol Pharmacol 1999, 56: 807–812.PubMedGoogle Scholar
- da Cunha JM, Rae GA, Ferreira SH, Cunha Fde Q: Endothelins induce ETB receptor-mediated mechanical hypernociception in rat hindpaw: roles of cAMP and protein kinase C. Eur J Pharmacol 2004, 501: 87–94. 10.1016/j.ejphar.2004.08.004PubMedView ArticleGoogle Scholar
- De-Melo JD, Tonussi CR, D'Orleans-Juste P, Rae GA: Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists. Pain 1998, 77: 261–269. 10.1016/S0304-3959(98)00098-0PubMedView ArticleGoogle Scholar
- Baamonde A, Lastra A, Villazon M, Bordallo J, Hidalgo A, Menendez L: Involvement of endogenous endothelins in thermal and mechanical inflammatory hyperalgesia in mice. Naunyn Schmiedebergs Arch Pharmacol 2004, 369: 245–251. 10.1007/s00210-003-0841-1PubMedView ArticleGoogle Scholar
- Balonov K, Khodorova A, Strichartz GR: Tactile allodynia initiated by local subcutaneous endothelin-1 is prolonged by activation of TRPV-1 receptors. Exp Biol Med (Maywood) 2006, 231: 1165–1170.Google Scholar
- Khodorova A, Navarro B, Jouaville LS, Murphy JE, Rice FL, Mazurkiewicz JE, Long-Woodward D, Stoffel M, Strichartz GR, Yukhananov R, Davar G: Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 2003, 9: 1055–1061. 10.1038/nm885PubMedView ArticleGoogle Scholar
- Zollner C, Shaqura MA, Bopaiah CP, Mousa S, Stein C, Schafer M: Painful inflammation-induced increase in mu-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 2003, 64: 202–210. 10.1124/mol.64.2.202PubMedView ArticleGoogle Scholar
- Hellwig N, Albrecht N, Harteneck C, Schultz G, Schaefer M: Homo- and heteromeric assembly of TRPV channel subunits. J Cell Sci 2005, 118: 917–928. 10.1242/jcs.01675PubMedView ArticleGoogle Scholar
- Gregan B, Jurgensen J, Papsdorf G, Furkert J, Schaefer M, Beyermann M, Rosenthal W, Oksche A: Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004, 279: 27679–27687. 10.1074/jbc.M403601200PubMedView ArticleGoogle Scholar
- Grantcharova E, Furkert J, Reusch HP, Krell HW, Papsdorf G, Beyermann M, Schulein R, Rosenthal W, Oksche A: The extracellular N terminus of the endothelin B (ETB) receptor is cleaved by a metalloprotease in an agonist-dependent process. J Biol Chem 2002, 277: 43933–43941. 10.1074/jbc.M208407200PubMedView ArticleGoogle Scholar
- Oksche A, Boese G, Horstmeyer A, Furkert J, Beyermann M, Bienert M, Rosenthal W: Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 2000, 57: 1104–1113.PubMedGoogle Scholar
- Oksche A, Boese G, Horstmeyer A, Papsdorf G, Furkert J, Beyermann M, Bienert M, Rosenthal W: Evidence for downregulation of the endothelin-B-receptor by the use of fluorescent endothelin-1 and a fusion protein consisting of the endothelin-B-receptor and the green fluorescent protein. J Cardiovasc Pharmacol 2000, 36: S44–7.PubMedView ArticleGoogle Scholar
- Strotmann R, Harteneck C, Nunnenmacher K, Schultz G, Plant TD: OTRPC4, a nonselective cation channel that confers sensitivity to extracellular osmolarity. Nat Cell Biol 2000, 2: 695–702. 10.1038/35036318PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.